Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The table above records the past week’s major catalyst events that occurred in the late-stage pipeline during the past week (see table for relevant dates), created using Citeline’s Biomedtracker.
The table lists drugs at Phase II or above for which an important catalyst was recorded during the week, according...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.
The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.
A second Phase III win for the investigational hypertension drug will help convince analysts that AstraZeneca can reach $80bn sales by 2030, but more pivotal trial successes will be needed over the next few years.
